Interferon mediated prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine lacking non-structural protein 1.

Adaptive Immunity Animals COVID-19 / immunology Chickens Gene Deletion Humans Influenza A virus / genetics Influenza Vaccines / genetics Influenza, Human / immunology Interferon Type I / immunology Mice Mice, Inbred C57BL Orthomyxoviridae Infections / immunology Vaccines, Attenuated / genetics Viral Nonstructural Proteins / genetics

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 11 2021
Historique:
received: 28 06 2021
accepted: 19 10 2021
entrez: 13 11 2021
pubmed: 14 11 2021
medline: 26 11 2021
Statut: epublish

Résumé

The influenza A non-structural protein 1 (NS1) is known for its ability to hinder the synthesis of type I interferon (IFN) during viral infection. Influenza viruses lacking NS1 (ΔNS1) are under clinical development as live attenuated human influenza virus vaccines and induce potent influenza virus-specific humoral and cellular adaptive immune responses. Attenuation of ΔNS1 influenza viruses is due to their high IFN inducing properties, that limit their replication in vivo. This study demonstrates that pre-treatment with a ΔNS1 virus results in an antiviral state which prevents subsequent replication of homologous and heterologous viruses, preventing disease from virus respiratory pathogens, including SARS-CoV-2. Our studies suggest that ΔNS1 influenza viruses could be used for the prophylaxis of influenza, SARS-CoV-2 and other human respiratory viral infections, and that an influenza virus vaccine based on ΔNS1 live attenuated viruses would confer broad protection against influenza virus infection from the moment of administration, first by non-specific innate immune induction, followed by specific adaptive immunity.

Identifiants

DOI: 10.1038/s41598-021-01780-8 PMID: 34773048 PMC: PMC8589955
pubmed: 34773048
doi: 10.1038/s41598-021-01780-8
pii: 10.1038/s41598-021-01780-8
pmc: PMC8589955
doi:

Substances chimiques

INS1 protein, influenza virus 0
Influenza Vaccines 0
Interferon Type I 0
Vaccines, Attenuated 0
Viral Nonstructural Proteins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22164

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI141226
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : Division of Intramural Research, National Institute of Allergy and Infectious Diseases
ID : R01AI141226
Organisme : NIAID NIH HHS
ID : R01 AI145870
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI097092
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93021C00014
Pays : United States
Organisme : NIAID NIH HHS
ID : 75N93019C00051
Pays : United States

Commentaires et corrections

Type : UpdateOf
Type : UpdateOf

Informations de copyright

© 2021. The Author(s).

Références

Taft, J. & Bogunovic, D. The Goldilocks zone of Type I IFNs: Lessons from human genetics. J. Immunol. 201, 3479–3485 (2018).
pubmed: 30530500 doi: 10.4049/jimmunol.1800764
Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36 (2014).
pubmed: 24362405 pmcid: 4084561 doi: 10.1038/nri3581
Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: A complex web of host defenses. Annu. Rev. Immunol. 32, 513–545 (2014).
pubmed: 24555472 pmcid: 4313732 doi: 10.1146/annurev-immunol-032713-120231
García-Sastre, A. T. strategies of interferon evasion by viruses. Cell Host Microbe 22, 176–184 (2017).
pubmed: 28799903 pmcid: 5576560 doi: 10.1016/j.chom.2017.07.012
Gori-Savellini, G., Valentini, M. & Cusi, M. G. Toscana virus NSs protein inhibits the induction of type I interferon by interacting with RIG-I. J. Virol. 87, 6660–6667 (2013).
pubmed: 23552410 pmcid: 3676095 doi: 10.1128/JVI.03129-12
Chan, Y. K. & Gack, M. U. A phosphomimetic-based mechanism of dengue virus to antagonize innate immunity. Nat. Immunol. 17, 523 (2016).
pubmed: 26998762 pmcid: 4837045 doi: 10.1038/ni.3393
Ronco, L. V., Karpova, A. Y., Vidal, M. & Howley, P. M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12, 2061–2072 (1998).
pubmed: 9649509 pmcid: 316980 doi: 10.1101/gad.12.13.2061
Smith, G. L., Talbot-Cooper, C. & Lu, Y. Advances in Virus Research 355–378 (Elsevier, 2018).
Edwards, M. R. et al. Differential regulation of interferon responses by Ebola and Marburg virus VP35 proteins. Cell Rep. 14, 1632–1640 (2016).
pubmed: 26876165 pmcid: 4767585 doi: 10.1016/j.celrep.2016.01.049
Nidetz, N. F., Gallagher, T. M. & Wiethoff, C. M. Inhibition of type I interferon responses by adenovirus serotype-dependent Gas6 binding. Virology 515, 150–157 (2018).
pubmed: 29288958 doi: 10.1016/j.virol.2017.12.016
Fortes, P., Beloso, A. & Ortin, J. Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport. EMBO J. 13, 704–712 (1994).
pubmed: 8313914 pmcid: 394862 doi: 10.1002/j.1460-2075.1994.tb06310.x
Qiu, Y. & Krug, R. M. The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A). J. Virol. 68, 2425–2432 (1994).
pubmed: 7908060 pmcid: 236720 doi: 10.1128/jvi.68.4.2425-2432.1994
García-Sastre, A. et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 252, 324–330 (1998).
pubmed: 9878611 doi: 10.1006/viro.1998.9508
Castanier, C. et al. MAVS ubiquitination by the E3 ligase TRIM25 and degradation by the proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like receptors. BMC Biol. 10, 44 (2012).
pubmed: 22626058 pmcid: 3372421 doi: 10.1186/1741-7007-10-44
Koliopoulos, M. G. et al. Molecular mechanism of influenza A NS1-mediated TRIM25 recognition and inhibition. Nat. Commun. 9, 1820 (2018).
pubmed: 29739942 pmcid: 5940772 doi: 10.1038/s41467-018-04214-8
Nemeroff, M. E., Barabino, S. M., Li, Y., Keller, W. & Krug, R. M. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3′ end formation of cellular pre-mRNAs. Mol. Cell 1, 991–1000 (1998).
pubmed: 9651582 doi: 10.1016/S1097-2765(00)80099-4
Kuo, R. L. et al. Role of N terminus-truncated NS1 proteins of influenza A virus in inhibiting IRF3 activation. J. Virol. 90, 4696–4705 (2016).
pubmed: 26912617 pmcid: 4836362 doi: 10.1128/JVI.02843-15
Krug, R. M. Functions of the influenza A virus NS1 protein in antiviral defense. Curr. Opin. Virol. 12, 1–6 (2015).
pubmed: 25638592 pmcid: 4470714 doi: 10.1016/j.coviro.2015.01.007
Mibayashi, M. et al. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J. Virol. 81, 514–524 (2007).
pubmed: 17079289 doi: 10.1128/JVI.01265-06
Richt, J. A. et al. Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J. Virol. 80, 11009–11018 (2006).
pubmed: 16943300 pmcid: 1642165 doi: 10.1128/JVI.00787-06
Nicolodi, C. et al. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1. Vaccine 37, 3722–3729 (2019).
pubmed: 31155415 doi: 10.1016/j.vaccine.2019.05.013
Morokutti, A., Muster, T. & Ferko, B. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans. Vaccine 32, 1897–1900 (2014).
pubmed: 24560674 doi: 10.1016/j.vaccine.2014.02.009
Mössler, C. et al. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Vaccine 31, 6194–6200 (2013).
pubmed: 24183981 doi: 10.1016/j.vaccine.2013.10.061
Morahan, P. S. & Grossberg, S. E. Age-related cellular resistance of the chicken embryo to viral infections. I. Interferon and natural resistance to myxoviruses and vesicular stomatitis virus. J. Infect. Dis. 121, 615–623 (1970).
pubmed: 4316147 doi: 10.1093/infdis/121.6.615
Plachý, J. et al. Protective effects of type I and type II interferons toward Rous sarcoma virus-induced tumors in chickens. Virology 256, 85–91 (1999).
pubmed: 10087229 doi: 10.1006/viro.1999.9602
Verhelst, J. et al. Functional comparison of Mx1 from two different mouse species reveals the involvement of loop L4 in the antiviral activity against influenza A viruses. J. Virol. 89, 10879–10890 (2015).
pubmed: 26292322 pmcid: 4621098 doi: 10.1128/JVI.01744-15
Haller, O., Arnheiter, H., Lindenmann, J. & Gresser, I. Host gene influences sensitivity to interferon action selectively for influenza virus. Nature 283, 660 (1980).
pubmed: 7354853 doi: 10.1038/283660a0
Staeheli, P., Grob, R., Meier, E., Sutcliffe, J. G. & Haller, O. Influenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol. Cell. Biol. 8, 4518–4523 (1988).
pubmed: 2903437 pmcid: 365527
Haller, O., Arnheiter, H., Horisberger, M., Gresser, I. & Lindenmann, J. Genetic-control of antiviral activities of interferon in mice (EXPERIENTIA Ser. 37, BIRKHAUSER VERLAG AG PO BOX 133 KLOSTERBERG 23, CH-4010 BASEL, SWITZERLAND, 1981).
Guo, L. et al. Pulmonary immune cells and inflammatory cytokine dysregulation are associated with mortality of IL-1R1 (−/−)mice infected with influenza virus (H1N1). Zool. Res. 38, 146–154 (2017).
pubmed: 28585438 pmcid: 5460083
Mizuta, T. et al. Antisense oligonucleotides directed against the viral RNA polymerase gene enhance survival of mice infected with influenza A. Nat. Biotechnol. 17, 583 (1999).
pubmed: 10385324 doi: 10.1038/9893
Fodor, E., Palese, P., Brownlee, G. G. & Garcia-Sastre, A. Attenuation of influenza A virus mRNA levels by promoter mutations. J. Virol. 72, 6283–6290 (1998).
pubmed: 9658066 pmcid: 109764 doi: 10.1128/JVI.72.8.6283-6290.1998
Solorzano, A. et al. Reduced levels of neuraminidase of influenza A viruses correlate with attenuated phenotypes in mice. J. Gen. Virol. 81, 737–742 (2000).
pubmed: 10675411 doi: 10.1099/0022-1317-81-3-737
Tashiro, M. & Homma, M. Pneumotropism of Sendai virus in relation to protease-mediated activation in mouse lungs. Infect. Immun. 39, 879–888 (1983).
pubmed: 6299951 pmcid: 348030 doi: 10.1128/iai.39.2.879-888.1983
Perler, L., Pfister, H., Schweizer, M., Peterhans, E. & Jungi, T. W. A bioassay for interferon type I based on inhibition of Sendai virus growth. J. Immunol. Methods 222, 189–196 (1999).
pubmed: 10022385 doi: 10.1016/S0022-1759(98)00198-7
Pavlovic, J., Zurcher, T., Haller, O. & Staeheli, P. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J. Virol. 64, 3370–3375 (1990).
pubmed: 2161946 pmcid: 249583 doi: 10.1128/jvi.64.7.3370-3375.1990
Hale, B. G., Albrecht, R. A. & García-Sastre, A. Innate immune evasion strategies of influenza viruses. Future Microbiol. 5, 23–41 (2010).
pubmed: 20020828 doi: 10.2217/fmb.09.108
Min, J. & Krug, R. M. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2′-5′ oligo (A) synthetase/RNase L pathway. Proc. Natl. Acad. Sci. 103, 7100–7105 (2006).
pubmed: 16627618 pmcid: 1459024 doi: 10.1073/pnas.0602184103
Li, S., Min, J., Krug, R. M. & Sen, G. C. Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA. Virology 349, 13–21 (2006).
pubmed: 16466763 doi: 10.1016/j.virol.2006.01.005
Gack, M. U. et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 5, 439–449 (2009).
pubmed: 19454348 pmcid: 2737813 doi: 10.1016/j.chom.2009.04.006
Das, K., Aramini, J. M., Ma, L., Krug, R. M. & Arnold, E. Structures of influenza A proteins and insights into antiviral drug targets. Nat. Struct. Mol. Biol. 17, 530 (2010).
pubmed: 20383144 pmcid: 2957899 doi: 10.1038/nsmb.1779
Vincent, A. L. et al. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 25, 7999–8009 (2007).
pubmed: 17933442 pmcid: 2099695 doi: 10.1016/j.vaccine.2007.09.019
Mueller, S. N., Langley, W. A., Carnero, E., Garcia-Sastre, A. & Ahmed, R. Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses. J. Virol. 84, 1847–1855 (2010).
pubmed: 19939929 doi: 10.1128/JVI.01317-09
Kochs, G. et al. Strong interferon-inducing capacity of a highly virulent variant of influenza A virus strain PR8 with deletions in the NS1 gene. J. Gen. Virol. 90, 2990–2994 (2009).
pubmed: 19726611 pmcid: 2887554 doi: 10.1099/vir.0.015727-0
Coch, C. et al. RIG-I activation protects and rescues from lethal influenza virus infection and bacterial superinfection. Mol. Ther. 25, 2093–2103 (2017).
pubmed: 28760668 pmcid: 5589155 doi: 10.1016/j.ymthe.2017.07.003
Ciancanelli, M. J., Abel, L., Zhang, S. & Casanova, J. Host genetics of severe influenza: From mouse Mx1 to human IRF7. Curr. Opin. Immunol. 38, 109–120 (2016).
pubmed: 26761402 pmcid: 4733643 doi: 10.1016/j.coi.2015.12.002
Horisberger, M. A., Staeheli, P. & Haller, O. Interferon induces a unique protein in mouse cells bearing a gene for resistance to influenza virus. Proc. Natl. Acad. Sci. USA 80, 1910–1914 (1983).
pubmed: 6188159 pmcid: 393720 doi: 10.1073/pnas.80.7.1910
Staeheli, P., Haller, O., Boll, W., Lindenmann, J. & Weissmann, C. Mx protein: Constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell 44, 147–158 (1986).
pubmed: 3000619 doi: 10.1016/0092-8674(86)90493-9
Horisberger, M. & Staritzky, K. D. Expression and stability of the Mx protein in different tissues of mice, in response to interferon inducers or to influenza virus infection. J. Interferon Res. 9, 583–590 (1989).
pubmed: 2794581 doi: 10.1089/jir.1989.9.583
Pavlovic, J., Haller, O. & Staeheli, P. Human and mouse Mx proteins inhibit different steps of the influenza virus multiplication cycle. J. Virol. 66, 2564–2569 (1992).
pubmed: 1548781 pmcid: 289059 doi: 10.1128/jvi.66.4.2564-2569.1992
Basler, C. F. & Garcia-Sastre, A. Viruses and the type I interferon antiviral system: Induction and evasion. Int. Rev. Immunol. 21, 305–337 (2002).
pubmed: 12486817 doi: 10.1080/08830180213277
Di Bisceglie, A. M. et al. Recombinant interferon alfa therapy for chronic hepatitis C. N. Engl. J. Med. 321, 1506–1510 (1989).
pubmed: 2509917 doi: 10.1056/NEJM198911303212204
Kao, J., Wu, N., Chen, P., Lai, M. & Chen, D. Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. 33, 998–1002 (2000).
pubmed: 11131465 doi: 10.1016/S0168-8278(00)80135-X
Mocellin, S., Pasquali, S., Rossi, C. R. & Nitti, D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: A systematic review and meta-analysis. J. Natl. Cancer Inst. 102, 493–501 (2010).
pubmed: 20179267 doi: 10.1093/jnci/djq009
Bohn, J., Gastl, G. & Steurer, M. Long-term treatment of hairy cell leukemia with interferon-α: Still a viable therapeutic option. memo-Mag. Eur. Med. Oncol. 9, 63–65 (2016).
Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E. & Hauser, P. Mood and cognitive side effects of interferon-alpha therapy. Semin. Oncol. 25, 39–47 (1998).
pubmed: 9482539
Sleijfer, S., Bannink, M., Van Gool, A. R., Kruit, W. H. & Stoter, G. Side effects of interferon-α therapy. Pharm. World Sci. 27, 423 (2005).
pubmed: 16341948 doi: 10.1007/s11096-005-1319-7
Corssmit, E. et al. Endocrine and metabolic effects of interferon-alpha in humans. J. Clin. Endocrinol. Metab. 81, 3265–3269 (1996).
pubmed: 8784081
Noisakran, S., Campbell, I. L. & Carr, D. J. Ectopic expression of DNA encoding IFN-alpha 1 in the cornea protects mice from herpes simplex virus type 1-induced encephalitis. J. Immunol. 162, 4184–4190 (1999).
pubmed: 10201945 doi: 10.4049/jimmunol.162.7.4184
Wong, J. P. et al. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 17, 1788–1795 (1999).
pubmed: 10194841 doi: 10.1016/S0264-410X(98)00439-3
Protzer, U., Nassal, M., Chiang, P. W., Kirschfink, M. & Schaller, H. Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proc. Natl. Acad. Sci. USA 96, 10818–10823 (1999).
pubmed: 10485909 pmcid: 17966 doi: 10.1073/pnas.96.19.10818
Arnaud, P. The interferons: Pharmacology, mechanism of action, tolerance and side effects. Rev. Med. Interne 23(Suppl 4), 449s–458s (2002).
pubmed: 12481400 doi: 10.1016/S0248-8663(02)00659-8
Pfeffer, L. M. et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res. 58, 2489–2499 (1998).
pubmed: 9635566
Vilcek, J. Fifty years of interferon research: Aiming at a moving target. Immunity 25, 343–348 (2006).
pubmed: 16979566 doi: 10.1016/j.immuni.2006.08.008
Oladunni, F. S. et al. Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. Nat. Commun. 11, 1–17 (2020).
doi: 10.1038/s41467-020-19891-7
Miorin, L. et al. SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc. Natl. Acad. Sci. USA 117, 28344–28354 (2020).
pubmed: 33097660 pmcid: 7668094 doi: 10.1073/pnas.2016650117
Martinez-Gil, L. et al. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J. Virol. 87, 1290–1300 (2013).
pubmed: 23175362 pmcid: 3554167 doi: 10.1128/JVI.02338-12
Wang, X. et al. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J. Virol. 74, 11566–11573 (2000).
pubmed: 11090154 pmcid: 112437 doi: 10.1128/JVI.74.24.11566-11573.2000
Bergmann, M. et al. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J. Virol. 74, 6203–6206 (2000).
pubmed: 10846107 pmcid: 112122 doi: 10.1128/JVI.74.13.6203-6206.2000
Talon, J. et al. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J. Virol. 74, 7989–7996 (2000).
pubmed: 10933707 pmcid: 112330 doi: 10.1128/JVI.74.17.7989-7996.2000
Romanova, J. et al. Preclinical evaluation of a replication-deficient intranasal ΔNS1 H5N1 influenza vaccine. PLoS ONE 4, e5984 (2009).
pubmed: 19543385 pmcid: 2694350 doi: 10.1371/journal.pone.0005984
Wressnigg, N. et al. Development of a live-attenuated influenza B ΔNS1 intranasal vaccine candidate. Vaccine 27, 2851–2857 (2009).
pubmed: 19366569 doi: 10.1016/j.vaccine.2009.02.087
Grimm, D. et al. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc. Natl. Acad. Sci. USA 104, 6806–6811 (2007).
pubmed: 17426143 pmcid: 1871866 doi: 10.1073/pnas.0701849104
Lampson, G. P., Tytell, A. A., Field, A. K., Nemes, M. M. & Hilleman, M. R. Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc. Natl. Acad. Sci. USA 58, 782–789 (1967).
pubmed: 5233474 pmcid: 335701 doi: 10.1073/pnas.58.2.782
Rathnasinghe, R. et al. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection. Emerg. Microbes Infect. 9, 2433–2445 (2020).
pubmed: 33073694 pmcid: 7655046 doi: 10.1080/22221751.2020.1838955

Auteurs

Raveen Rathnasinghe (R)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY, 100229, USA.
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Mirella Salvatore (M)

Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

Hongyong Zheng (H)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY, 100229, USA.

Sonia Jangra (S)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY, 100229, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Thomas Kehrer (T)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY, 100229, USA.
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Ignacio Mena (I)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY, 100229, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Michael Schotsaert (M)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY, 100229, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Thomas Muster (T)

Department of Dermatology, University of Vienna Medical School, 1090, Wien, Austria.

Peter Palese (P)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY, 100229, USA.
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.

Adolfo García-Sastre (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1124, New York, NY, 100229, USA. adolfo.gracia-sastre@mssm.edu.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. adolfo.gracia-sastre@mssm.edu.
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. adolfo.gracia-sastre@mssm.edu.
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA. adolfo.gracia-sastre@mssm.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Interferon mediated prophylactic protection...
questionsmedicales.fr › Eucaryotes › Animaux › Interferon mediated prophylactic protection...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Interferon mediated prophylactic protection...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Oiseaux › Poulets › Interferon mediated prophylactic protection...
questionsmedicales.fr › Phénomènes génétiques › Mutagenèse › Délétion de séquence › Délétion de gène › Interferon mediated prophylactic protection...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Interferon mediated prophylactic protection...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN de polarité négative › Orthomyxoviridae › Influenzavirus A › Virus de la grippe A › Interferon mediated prophylactic protection...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins antigrippaux › Interferon mediated prophylactic protection...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Grippe humaine › Interferon mediated prophylactic protection...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Interferon mediated prophylactic protection...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Interferon mediated prophylactic protection...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Interferon mediated prophylactic protection...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus à ARN › Infections à Orthomyxoviridae › Interferon mediated prophylactic protection...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins atténués › Interferon mediated prophylactic protection...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines virales › Protéines virales non structurales › Interferon mediated prophylactic protection...